1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Spyre Therapeutics Acquires Spyre Therapeutics

M&A Deal Summary

Spyre Therapeutics Acquires Spyre Therapeutics

On June 22, 2023, Spyre Therapeutics acquired life science company Spyre Therapeutics

Acquisition Highlights
  • This is Spyre Therapeutics’ 1st transaction in the Life Science sector.
  • This is Spyre Therapeutics’ 1st transaction in the United States.
  • This is Spyre Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2023-06-22
Target Spyre Therapeutics
Sector Life Science
Buyer(s) Spyre Therapeutics
Deal Type Add-on Acquisition

Target

Spyre Therapeutics

San Francisco, California, United States
Spyre Therapeutics combines antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize the efficacy, safety, and convenience of treatments for inflammatory bowel disease. Spyre Therapeutics is based in San Francisco, California.

Search 214,744 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Spyre Therapeutics

Waltham, Massachusetts, United States
Category Company
Founded 2013
Sector Life Science
Employees73
Revenue 1M USD (2023)
DESCRIPTION

Spyre Therapeutics is a biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Spyre Therapeutics was incorporated in 2013 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal